Skip to main navigation Skip to search Skip to main content

Takeda Pharmaceutical: Phase 2 Dose Ranging Study to Evaluate Safety of 2 Dose Regimens of Intravenous TAK-954 for Prophylaxis & Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large & Small-Bowel Resection

Stony Brook University

Project: Research

Project Details

StatusFinished
Effective start/end date06/30/20 → 03/9/24

Funding

  • Pharmaceutical Research Associates Incorporated: $85,639.40